Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2275 of 3173 entries
View as:

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Phase: N/A Priority: Normal
NCT ID: NCT00147550 Org: User:
Start: 02/29/04 End: 07/31/13 Due: 07/31/14

Axitinib Therapy Management Study

Phase: N/A Priority: Normal
NCT ID: NCT04555603 Org: User:
Start: 09/15/20 End: 02/22/21 Due: 02/22/22

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00537615 Org: User:
Start: 09/30/07 End: 10/31/07 Due: 10/31/08

Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Phase: N/A Priority: Normal
NCT ID: NCT00708708 Org: User:
Start: 06/30/08 End: 12/31/13 Due: 12/31/14

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00306254 Org: User:
Start: 03/31/06 End: 07/31/07 Due: 07/31/08

Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia

Phase: N/A Priority: Normal
NCT ID: NCT04234698 Org: User:
Start: 03/22/21 End: 10/31/21 Due: 10/31/22

A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03398473 Org: User:
Start: 01/25/18 End: 05/07/18 Due: 05/07/19

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06436703 Org: User:
Start: 05/23/24 End: 02/03/25 Due: 02/03/26

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT02473497 Org: User:
Start: - End: - Due: -

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase: N/A Priority: Normal
NCT ID: NCT04649359 Org: User:
Start: 02/02/21 End: 12/31/25 Due: 12/31/26

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

Phase: N/A Priority: Normal
NCT ID: NCT04580797 Org: User:
Start: 10/02/20 End: 01/11/21 Due: 01/11/22

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT00037791 Org: User:
Start: 12/31/99 End: 09/30/02 Due: 09/30/03

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02629289 Org: User:
Start: 08/31/15 End: 06/30/16 Due: 06/30/17

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Phase: N/A Priority: Normal
NCT ID: NCT05611801 Org: User:
Start: 12/09/22 End: 09/10/28 Due: 09/10/29

Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe

Phase: N/A Priority: Normal
NCT ID: NCT05194579 Org: User:
Start: 02/10/22 End: 08/10/22 Due: 08/10/23

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT00759564 Org: User:
Start: 11/30/08 End: 03/31/10 Due: 03/31/11

A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users

Phase: N/A Priority: Normal
NCT ID: NCT01825447 Org: User:
Start: 07/31/13 End: 09/30/13 Due: 09/30/14

A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00651300 Org: User:
Start: 04/30/03 End: 03/31/04 Due: 03/31/05

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00942968 Org: User:
Start: 06/30/09 End: 06/30/13 Due: 06/30/14

Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)

Phase: N/A Priority: Normal
NCT ID: NCT00772941 Org: User:
Start: 02/28/09 End: 12/31/12 Due: 12/31/13

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT01577381 Org: User:
Start: 08/31/12 End: 10/31/13 Due: 10/31/14

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03878719 Org: User:
Start: 08/03/20 End: 08/19/22 Due: 08/19/23

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

Phase: N/A Priority: Normal
NCT ID: NCT05093205 Org: User:
Start: 10/25/21 End: 07/06/22 Due: 07/06/23

The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Phase: N/A Priority: Normal
NCT ID: NCT04198844 Org: User:
Start: 11/18/19 End: 03/31/20 Due: 03/31/21

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Phase: N/A Priority: Normal
NCT ID: NCT03135834 Org: User:
Start: 04/24/17 End: 10/25/22 Due: 10/25/23